RVRC · Revium Rx.
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Price & Indicators
The closing range uses available history since Jan 5, 2026; less than a full year is stored.
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Health Information Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RVRC
this stock
Revium Rx.
|
$86.84M | — | — | — | — |
|
VEEV
Veeva Systems Inc
|
$51.80B | +43.6% | +28.1% | 52.4 | 3.0% |
|
PMDIY
Pro Medicus Ltd.
|
$12.77B | -26.4% | — | — | 0.0% |
|
BTSG
BrightSpring Health Services, Inc.
|
$12.34B | +66.5% | +28.2% | 37.8 | 6.1% |
|
TEM
Tempus AI, Inc.
|
$12.01B | +14.8% | +83.4% | — | 13.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RVRC | +186.0% | +5.9% | — | +0.0% | +175.0% |
| SPY | +0.1% | -0.4% | +15.1% | +0.4% | +12.9% |
| vs SPY | +185.9% | +6.3% | — | -0.4% | +162.1% |